Key result
Patients with type 2 diabetes had significantly higher A-FABP (50.0 vs 28.6 ng/mL, P<0.0001) and lower adiponectin levels than healthy controls, correlating with markers of vascular damage.
Why the study?
Are adipokine levels altered in patients with type 2 diabetes and do they correlate with markers of vascular damage compared to healthy controls?
Cross-Sectional (n=77)
Are adipokine levels altered in patients with type 2 diabetes and do they correlate with markers of vascular damage compared to healthy controls?
In patients with type 2 diabetes, higher A-FABP and lower adiponectin levels correlate with indicators of vascular damage, suggesting a potential contribution to cardiovascular risk.
Supports adipokine role in T2D vascular damage; hypothesis-generating and should not yet alter practice.
BACKGROUND: In this study we compared levels of selected adipokines between patients with type 2 diabetes (T2D) and healthy individuals and we determined their relationship with early vascular damage markers. METHODS: Seventy-seven subjects: 56 patients with T2D (34 men and 22 women) and 21 healthy controls (8 men and 13 women) were examined in this cross-sectional study. Selected adipokines [adiponectin, adipocyte fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF-21), C1q/TNF-related protein 9 (CTRP-9), and allograft inflammatory factor-1 (AIF-1)] with possible cardiovascular impact were measured in all participants. To identify markers of vascular damage von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) and arterial stiffness parameters were examined in all the subjects. RESULTS: When compared with healthy controls, T2D had significantly higher levels of A-FABP [50.0 (38.1-68.6) vs. 28.6 (23.6-32.9) ng/mL, P < 0.0001] and lower levels of adiponectin [5.9 (4.3-9.0) vs. 11.3 (8.7-14.8) μg/mL, P < 0.0001]. Differences in other adipokines were not statistically significant. Adiponectin level correlated negatively with vWF levels (ρ = -0.29, P < 0.05) and PAI-1 (ρ = -0.36, P < 0.05) and A-FABP positively with vWF (ρ = 0.61, P < 0.05) and PAI-1 (ρ = 0.47, P < 0.05) and augmentation index (ρ = 0.26, P < 0.05). Multivariate regression analysis showed independent association between A-FABP and vWF (b = 0.24, P < 0.05). CONCLUSIONS: Patients with T2D have significantly higher levels of A-FABP and lower levels of adiponectin. These adipokines correlate with indicators of vascular damage and could contribute to cardiovascular risk in patients with T2D. A-FABP may participate in direct endothelium damage.
No takes yet. Share an insight, caveat, or question.
Spurná et al. (2018) conducted a cross-sectional in Type 2 diabetes (n=77). Type 2 diabetes vs. Healthy controls was evaluated on A-FABP levels (ng/mL) (p=<0.0001). Patients with type 2 diabetes had significantly higher A-FABP (50.0 vs 28.6 ng/mL, P<0.0001) and lower adiponectin levels than healthy controls, correlating with markers of vascular damage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: